AI Article Synopsis
- Study investigates the roles of von Willebrand factor (VWF) and its cleaver, ADAMTS13, in predicting major adverse cardiovascular outcomes (MACE) in patients undergoing percutaneous coronary intervention (PCI).
- Analyzed data from 701 patients, finding that VWF levels were linked to higher MACE and mortality in those with acute coronary syndrome (ACS), but not in stable coronary artery disease (SCAD).
- The study concludes that VWF is a critical risk marker for ACS, while ADAMTS13 shows no predictive value for MACE or mortality in either ACS or SCAD.
Article Abstract
Background: Von Willebrand factor (VWF) and its cleaving protease a disintegrin-like and metalloprotease with thrombospondin type I repeats 13 (ADAMTS13) are pivotal mediators of thrombosis and are associated with the progression of atherosclerosis. We investigated the impact of VWF, ADAMTS13 and VWF/ADAMTS13 on long-term major adverse cardiovascular outcomes (MACE) in patients undergoing percutaneous coronary intervention (PCI).
Methods: We analysed 701 patients undergoing PCI between 2003 and 2006. VWF and ADAMTS13 antigen levels were measured before PCI. As primary endpoint, we investigated MACE, a composite of all-cause mortality, myocardial infarction or ischemic stroke during 8 years of follow-up. As secondary endpoint, we investigated all-cause mortality.
Results: Mean age was 63.8 years, 496 (70.8%) were male. Acute coronary syndrome (ACS) was diagnosed in 347 (49.5%) patients, stable coronary artery disease (SCAD) in 354 (50.5%). During follow-up 228 (32.5%) patients experienced MACE, and 161 (23.0%) died. In ACS patients, VWF was significantly associated with MACE (HR 1.402 (95%CI 1.003-1.959), p = 0.048), whereas ADAMTS13 and VWF/ADAMTS13 had no predictive value. In SCAD, neither VWF, ADAMTS13, nor VWF/ADAMTS13 correlated with MACE. VWF was significantly associated with all-cause death in ACS patients (HR 1.841 (95%CI 1.187-2.856), p = 0.006), but not in SCAD (1.394 (95%CI 0.856-2.269), p = 0.181). ADAMTS13 and VWF/ADAMTS13 were not correlated with ACS and SCAD, respectively.
Conclusion: VWF but not ADAMTS13 and VWF/ADAMTS13 was associated with MACE and mortality in patients with ACS but not SCAD. This finding highlights the importance of VWF as an essential marker of risk in patients with ACS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.thromres.2020.08.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Imbalanced VWF-ADAMTS13 axis contributes to the detrimental impact of a preceding respiratory tract infection on stroke.
Blood Adv
January 2025
University of Iowa, Iowa city, Iowa, United States.
Respiratory tract infections (RTIs) caused by bacteria or viruses are associated with stroke severity. Recent studies have revealed an imbalance in the von Willebrand factor (VWF)-ADAMTS13 axis in patients with RTIs, including COVID-19. We examined whether this imbalance contributes to RTI-mediated stroke severity.
View Article and Find Full Text PDFDetermination of the Level of von Willebrand Factor, ADAMTS13, and Ratio of ADAMTS13:von Willebrand Factor in Sickle Cell Disease Patients.
Ann Afr Med
November 2024
Department of Haematology, Ondo State University of Medical Sciences, Ondo City, Ondo State, Nigeria.
Article Synopsis
- * The study aims to assess the levels of von Willebrand factor (VWF), ADAMTS13, and their ratio in SCD patients in Calabar to understand their roles in the development of VOC.
- * Results show that VWF levels were significantly higher in patients experiencing VOC compared to those in steady states and healthy controls, while ADAMTS13 levels did not show significant differences across groups.
vWF-ADAMTS13 axis in acute pancreatitis: Unveiling the hidden player or a mere bystander?
Pancreatology
November 2024
John Hopkins University, Baltimore, USA. Electronic address:
Circulating microRNAs targeting coagulation and fibrinolysis in patients with severe COVID-19.
Thromb J
September 2024
HUS Diagnostic Center, Department of Clinical Chemistry, University of Helsinki and Helsinki University Hospital, POB 720, Helsinki, 00029, Finland.
Background: Coronavirus-19 disease (COVID-19) frequently causes coagulation disturbances. Data remains limited on the effects of microRNAs (miRNAs) on coagulation during COVID-19 infection. We aimed to analyze the comprehensive miRNA profile as well as coagulation markers and blood count in hospitalized COVID-19 patients.
View Article and Find Full Text PDFThe Phenomenon of Thrombotic Microangiopathy in Cancer Patients.
Int J Mol Sci
August 2024
Department of Obstetrics, Gynecology and Perinatal Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str. 8-2, 119991 Moscow, Russia.
Article Synopsis
- - Thrombotic microangiopathy (TMA) is a group of disorders where small blood vessel clotting causes organ damage, including conditions like thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome (HUS), each with unique causes and impacts on health.
- - In TMA, inflammation leads to endothelial damage and activates platelet and coagulation processes, often linked to low ADAMTS13 enzyme levels, particularly in cancer patients undergoing chemotherapy, which raises thrombotic risk by increasing the VWF/ADAMTS13 ratio.
- - Treatment focuses on diagnosing the specific cause and may include therapies to inhibit complement activation, supportive care, and plasmapheresis
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!